By Brad Sorensen, CFA

NASDAQ:TELO

READ THE FULL TELO RESEARCH REPORT

Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company just released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”

The company, however, is not stopping there and just released new preclinical test results that showed the potential for Telomir-1 to reverse causes of Type 2 diabetes. According to the American Diabetes Association, the annual cost of diabetes in 2022 was $412.9 billion, with $306.6 billion of that being direct medical costs. And according to the CDC, there were over 38 million Americans suffering from the condition in 2021, a number that, unfortunately, is expected to expand in the coming years.

In an effort to alleviate the strain of the condition, Telomir Pharmaceuticals engaged in preclinical testing of Telomir-1 on zebrafish models of Type 2 diabetes. According to the company, the results from those tests were quite encouraging, with company management noting key findings such as:

• Reversal of Hyperglycemia and Insulin Resistance: Telomir-1 demonstrated dose-dependent efficacy in normalizing blood glucose and reducing insulin levels, restoring glucose homeostasis.
• Significantly Reduced HOMA-IR Values: Telomir-1 showed a substantial improvement in insulin sensitivity to near pre-diabetes values.
• Enhanced Glucose Clearance: Significant improvements in Oral Glucose Tolerance Test (OGTT) results highlighted Telomir-1’s impact on glucose metabolism.
• Increased Survival Rates: Treated models exhibited improved survival compared to controls, showcasing Telomir-1’s comprehensive therapeutic potential.

This announcement adds to the list of conditions that Telomir-1 has the potential to treat by attacking the underlying causes of the conditions and not just the symptoms. The company is continuing to zero in on all of the mechanisms that cause Telomir-1 to have these positive impacts and recently explained that Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these underlying causes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues and reducing these levels could have a major impact on a wide variety of conditions.

The company announced that, in addition to these potential groundbreaking results, it’s not going to stand still and plans to advance additional research in such areas as:

• Progeria Studies: Evaluating Telomir-1’s effects on human progeria cell lines and progeria nematode models to investigate its impact on accelerated aging and telomere function and stability.
• Diabetic Mouse Models: Further validating Telomir-1’s efficacy in mammalian model of Type 2 diabetes.
• Alzheimer’s Disease: Initiating studies to assess Telomir-1’s potential in mitigating cognitive decline and neurodegeneration.
• Osteoarthritis and Inflammatory Diseases: Evaluating Telomir-1’s role in managing joint health and other age-related inflammatory conditions.
• Cancer Models: Exploring Telomir-1’s application in combating age-related oncological conditions.

It's this extensive experience and record of success, combined with the test results we’ve seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the company that develops it. As a result of the new potential business from a possible breakthrough diabetes treatment, we are boosting our price target to $12.15 per share. We urge investors who have a higher risk tolerance to take a look at TELO and consider investing in a company at a very early stage that has a large potential upside, with a low float and positive news flow likely in the near future, providing potential fuel to the stock.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.